Peripheral Stem Cell Transplant Program - CHI Health, Nebraska (NE) - Southwest Iowa (IA)

The CHI Health Peripheral Stem Cell Transplant Program, offered at CHI Health Immanuel and CHI Health Bergan Mercy, provides this standard treatment option for patients with cancer including but not limited to multiple myeloma and lymphomas.

An Autologous Stem Cell Transplant is performed by collecting and cryopreserving (freezing) a patient's stem cells. This is followed by high-dose chemotherapy to reduce or eliminate disease. The stem cells are then re-infused back into the patient's body through a central venous catheter. The stem cells will engraft in the destroyed bone marrow and begin producing normal blood cells.

More autologous transplants are performed in patients with multiple myeloma each year than any other disease. Autologous transplants have a low mortality rate, high response rate and tend to prolong the period of remission in many patients. Eligible patients who are given a combination of novel drugs (thalidomide, lenalidomide and bortezomib) plus dexamethasone, followed by a stem cell transplant, experience superior results. The success of a transplant also depends on the type and stage of the disease, patient age and general health.

The Multidisciplinary Stem Cell Transplant Team provides transformational care for its patients, and furthers CHI Health's mission to treat the whole person—body, mind and spirit. 

FACT Accreditation

FACT sealCHI Health Immanuel's Autologous Stem Cell Transplant Program received FACT accreditation in January, 2015. FACT conducted an on-site evaluation of CHI Health Immanuel, and determined that CHI Health Immanuel is in compliance with FACT standards, as well as the U.S. Food and Drug Administration's current rules for Good Tissue Practice. The standards for accreditation are evidence-based requirements set by world-renowned experts in the field of cellular therapy.

About FACT

Foundation for the Accreditation of Cellular Therapy (FACT) is an internationally recognized accrediting body for hospitals and medical institutions offering stem cell transplant therapy. It is the only international standard used in Europe, Canada, Australia, New Zealand and the USA. Managed care organizations and health insurance plans use FACT accreditation as a deciding factor for designating Centers of Excellence. Since 2007, FACT Accreditation has been used in determining U.S. News & World Report's rankings of transplant centers for the “America's Best Hospitals” and “America's Best Children's Hospital's” list.